CompletedPhase 1/2

A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma

France2 participantsStarted 2019-01-15

Plain-language summary

The purpose of this study is to evaluate the safety and the feasibility, and the success of engraftment of the introduction of Cal-1 gene-transduced haematopoietic cell populations (Ttn and HSPCtn) in patients with HIV-1-related high-risk lymphoma.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 1\. Intermediate- or high-grade B-cell non-Hodgkin lymphoma, meeting 1 of the following criteria:
✓. Hodgkin lymphoma, meeting 1 of the following criteria:
✓. High-risk lymphoma requiring a treatment with combined chemotherapy and autologous stem cell transplantation (ASCT)

What they're measuring

Incidence of adverse event post transplant

Timeframe: 24 months post-transplant

Success of hematopoietic stem cell engraftment

Timeframe: 24 months post-transplant

Trial details

NCT IDNCT03593187

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-07-28

View on ClinicalTrials.gov More HIV-1 Infection trials